Participated · Convertible Note · Mar 2026

Imperative Care is a commercial-stage medical technology company focused on advancing treatments for thromboembolic disease, including ischemic stroke and other vascular diseases caused by blood clots. Its commercially available product portfolio includes the Zoom Stroke System, the Symphony Thrombectomy System, and the Prodigy Thrombectomy System, which have been used in more than 78,000 procedures. The company is also developing the Telos endovascular robotic platform, currently in development and not approved for sale. Imperative Care said the $100 million convertible note financing will support commercialization of its existing stroke and vascular portfolios, next‑generation product development, and clinical evidence generation. The company is based in Campbell, Calif., and announced a new board appointment tied to the financing.

Participated · Series A · Apr 2025

Phantom Neuro develops a minimally invasive neural interface platform called Phantom X to enable intuitive control of prosthetic limbs and robotic exoskeletons. Phantom X, originally developed at the Johns Hopkins University School of Medicine, is designed to restore natural movement by making assistive devices function as seamless extensions of the body. The company reported that its ASCENT study demonstrated 94% accuracy decoding real-time gestures across 11 essential hand and wrist movements. Phantom Neuro has received FDA Breakthrough Device and TAP designations for Phantom X, which may expedite regulatory approvals. The company plans to use new funding to accelerate preclinical testing, complete first-in-human trials, pursue regulatory submissions, and expand R&D for broader control applications beyond prosthetic limbs. Phantom Neuro is headquartered in Austin, Texas and has raised $28 million in total funding to date. Phantom Neuro develops a low-power, high-accuracy system intended to provide lifelike control of robotic orthopedic technologies. The company is positioned in the neurotech sector and is based in Austin, TX. Its core product targets control interfaces for robotic orthopedics, emphasizing low power consumption and high accuracy. The article does not disclose operating metrics such as revenue or user counts. Phantom Neuro announced a $6 million expanded seed financing, which increases its total funding to $9.5 million. The funding supports the company’s continued development of its control system for robotic orthopedic applications. Phantom Neuro is a neurotechnology company based in Austin, Texas and Baltimore, Maryland that is creating a system to enable lifelike control of robotic orthopedic technologies such as prosthetic limbs and exoskeletons. Its solution combines low-risk implantable sensors, AI, and enabling software to provide control of existing and next-generation orthopedic devices. The company is led by founder and CEO Dr. Connor Glass. Phantom Neuro raised seed funding to expand its operations and business reach. The $3.26M round was led by LionBird Ventures with participation from Draper Associates, Breakout Ventures, Blackrock Neurotech, Capital Factory, and private investors. As part of the financing, LionBird partner Robert Lord will join the board and LionBird Managing Partner Ed Michael will join as a board observer.

Participated · Equity · Apr 2023

Founded in 2015, EquipmentShare blends a nationwide equipment rental business with a cloud-enabled technology stack aimed at improving productivity on construction sites. Its proprietary T3 platform offers telematics, fleet management, connected jobsite sensors, and a digital marketplace for equipment rentals. The company has rapidly grown into one of the largest equipment rental providers in the United States and continues to broaden its national footprint. EquipmentShare focuses on delivering data-driven insights and digitally integrated asset management to boost efficiency and collaboration in the construction industry. Management is prioritizing expanded technology investments and the scaling of its rental operations. A recently secured $2.75 billion credit facility strengthens its capital structure, extends debt maturities to 2030, and provides ample liquidity to fund these growth initiatives.

Participated · Series B · Jul 2022

DELFI Diagnostics is a Palo Alto–based developer of blood-based cancer detection tests that use fragmentomics and advanced machine-learning methods applied to whole-genome sequencing data. The platform analyzes patterns of cell-free DNA fragments to detect chaotic signatures left by cancer cells. DELFI has commercialized FirstLook Lung, a blood test that evaluates DNA fragment patterns to indicate the presence of lung cancer. In an independent validation, FirstLook Lung demonstrated 80% sensitivity in a screening population, including early-stage detection, and a 99.8% negative predictive value. The company received an equity investment from the Merck Global Health Innovation Fund and intends to use the funds to accelerate development and commercialization of its cancer detection solutions. Led by CEO Susan Tousi, DELFI positions its fragmentomics and AI technologies as a potential high-precision, population-scale approach to early cancer detection at a disruptive price. Delfi Diagnostics has built a platform that analyzes cell-free DNA fragments across the entire genome using a proprietary, scalable whole-genome fragmentation approach. The platform is designed to enable a single, low-cost, and straightforward lab process for multiple liquid-biopsy tests and leverages machine learning to deliver high-performing results. Led by CEO and founder Victor Velculescu, the company is validating its technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG. Delfi is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring. The company intends to use the funds raised to continue development and commercialization of single-cancer early detection, multi-cancer early detection, and treatment-monitoring blood tests. Headquarters are listed in Palo Alto, CA and Baltimore, MD. Delfi Diagnostics is a Baltimore-based company developing a new class of high-performance, affordable liquid biopsy tests for early cancer detection. Its platform leverages machine learning and genome-wide fragmentation profiles of cell-free DNA to detect evidence of tumors from a blood sample and to pinpoint tumor location. The company is applying this platform to a range of products to detect specific cancers, such as lung cancer in at-risk individuals, and to identify multiple cancers in any individual. Delfi plans to use the funding to expand its team of cancer researchers and machine learning experts and to validate its next-generation liquid biopsy technology through multiple prospective clinical studies. Financially, Delfi raised $100M in a Series A financing led by OrbiMed. The company is led by founder and CEO Victor Velculescu.

Participated · Series B · Jul 2020

Thrive Earlier Detection is developing CancerSEEK, a liquid biopsy blood test intended to detect many cancers at earlier stages of disease. The company aims to incorporate CancerSEEK into routine medical care and, used alongside standard-of-care screening, shift diagnoses to earlier, potentially curable stages. In April, Thrive published data from the first prospective, interventional study of a multi-cancer screening test in an asymptomatic population, and company statements reference a real-world study of 10,000 individuals showing the test more than doubled cancers first detected by screening. Thrive says it will continue to work with stakeholders to remove barriers to timely access, including pursuing future reimbursement. The recent financing provides capital to advance CancerSEEK into a registrational trial. Overall, Thrive’s stated mission is to extend and save lives by making earlier cancer detection a routine part of care. Thrive Earlier Detection is building CancerSEEK, a liquid‑biopsy blood test designed to detect multiple cancer types at earlier stages and to be administered during routine medical care. CancerSEEK interrogates circulating tumor DNA mutations and cancer‑associated protein markers; in a retrospective study published in Science it demonstrated greater than 99% specificity and sensitivities of 69%–98% for five cancers that lack screening tests. Thrive holds an exclusive license to CancerSEEK from Johns Hopkins and the technology was pioneered by Bert Vogelstein, Kenneth Kinzler and Nickolas Papadopoulos. The company plans to integrate real‑world data and machine learning and to offer an integrated service for result interpretation, confirmatory diagnostics and clinical care guidance to embed the test in primary care workflows. Thrive has received FDA Breakthrough Device designation for pancreatic and ovarian cancer detection and is conducting the DETECT prospective study (10,000 enrolled to date in the specified cohort) with Johns Hopkins and Geisinger to generate evidence for regulatory approvals, guideline inclusion and reimbursement. The company launched in 2019 and recently closed a $110M Series A to advance commercialization and additional clinical studies.